Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
US FDA’s 2022 Novel Agent Actions Suggest Acceleration In Use Of Complete Response Letters
Mar 10 2022
•
By
Bridget Silverman
US FDA has been using its "complete response" stamp more frequently. • Source: Nielsen Hobbs; the Pink Sheet | Alamy image
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Complete Response Letters
More from Product Reviews